The Reddit post's core claim mostly holds up: many DSO offers are not a simple one-time sale price. They are a bundle of separate promises, usually a cash payment now plus a multi-year employment contract, earnout or holdback conditions, management-fee drag, and sometimes illiquid rollover equity. That does not make every DSO deal a scam, but it does mean the headline number can overstate what the seller actually controls, keeps, and receives on time.
McLerran & Associates says a conventional DSO structure can be "70-90% cash at closing" with "10%-30%" held back as an earnout, and says modern variants often include retained practice equity or parent-company stock instead of pure cash. Source: https://dentaltransitions.com/unpacking-dso-deal-structures/
Omni Practice Group describes the same split more bluntly. It says some buyers wrap accounts receivable into the price so a dentist thinks they got "100% of last year's collections," but "No, they're not. They're offering you 70% of last year's collections and they will pay the market rate for the accounts receivable." Omni then says the DSO usually pays "around 70% of the purchase price at closing," while the seller finances the last "30%" and only gets that money over a three-year work-back period if production or net income stay high enough. Source: https://omni-pg.com/what-dentists-need-to-know-before-selling-to-a-dso/
That is the closest direct confirmation of the Reddit theory. The seller is not just selling an asset. The seller is also betting that they will keep working, that the practice will keep producing, and that the buyer's post-close changes will not reduce the very metrics that unlock the unpaid part of the deal.
McLerran defines a holdback or earnout as money withheld at close and paid later only if the owner fulfills post-closing employment obligations and keeps revenue or EBITDA at pre-close levels. Source: https://dentaltransitions.com/unpacking-dso-deal-structures/
US Dental Practices says the same thing in simpler language: only the cash-at-close portion is guaranteed, while earnouts depend on performance targets and equity rollover is illiquid until the DSO itself is sold. It also says DSO employment periods are typically "three to five years," while an individual buyer may only ask for "30 to 90 days" of transition help. Source: https://www.usdentalpractices.com/blog/selling-dental-practice-to-dso
Omni adds the practical problem: if the buyer changes culture, staffing, or operations after closing, the seller can still miss the target and lose the deferred payment. Its warning is explicit: if you are counting on that last 30%, "there is a bit of a gamble." Source: https://omni-pg.com/what-dentists-need-to-know-before-selling-to-a-dso/
That is why the Reddit post resonates. A dentist can believe they sold for a large multiple, but a meaningful chunk of the economics is really compensation for staying employed and hitting operating benchmarks after surrendering control.
McLerran says JV-style deals usually impose a management fee of "typically 5-9% of revenue." It also warns that recap upside can depend on whether the higher parent-company multiple is applied before or after that fee is deducted. Source: https://dentaltransitions.com/unpacking-dso-deal-structures/
Omni is even more direct: "Most will charge the practice a 5% - 15% management fee." It warns that the doctor can miss their required net-income number "to no fault of his own" because the buyer changed staffing or added an associate while also charging the fee. Source: https://omni-pg.com/what-dentists-need-to-know-before-selling-to-a-dso/
This matters because management fees reduce the exact profit pool that often determines whether the deferred 30% gets paid. In other words, the buyer can legitimately say the price was generous while the seller discovers later that the post-close hurdle was harder than it looked.
McLerran says DSO deals are often priced on EBITDA, not collections, and says DSO valuations can exceed doctor-to-doctor values "sometimes by as much as 300%." It also provides an example where a practice sold at "7 X EBITDA" could later recap at "14 X EBITDA," doubling the value of liquidated JV equity. Source: https://dentaltransitions.com/unpacking-dso-deal-structures/
That upside is real, but it is conditional. DDS Lawyers warns that the headline number is "rarely the whole story" and says normalized EBITDA is often adjusted downward during diligence. Its advice is to demand specificity on how EBITDA will be calculated because DSOs know where the ambiguity sits. Source: https://www.ddslawyers.com/what-dental-practice-owners-need-to-know-about-letters-of-intent-when-selling-to-a-dental-service-organizatio
Omni makes the same point from the seller side: it says some doctors claim they sold for "5 or 6 times EBITDA" only to learn that management fees and note payments were folded into the calculation, so it "truly wasn't anywhere 6 times EBITDA." Source: https://omni-pg.com/what-dentists-need-to-know-before-selling-to-a-dso/
So the Reddit complaint is not just that the price is deferred. It is that the measurement system itself can change between teaser offer, LOI, diligence, and post-close payout.
DDS Lawyers is especially useful here. It says LOIs are "far more powerful than" the usual claim that they are non-binding. It says sellers are commonly pushed into an exclusivity period of "60 to 120 days," and that unresolved terms tend to be settled in the DSO's favor because the DSO and its counsel repeat this process constantly. Source: https://www.ddslawyers.com/what-dental-practice-owners-need-to-know-about-letters-of-intent-when-selling-to-a-dental-service-organizatio
That supports another part of the Reddit thesis: the economic deal is not just the purchase price. The structure of exclusivity, diligence, employment, and post-close contingencies gives the buyer repeated chances to improve its position after the seller has psychologically committed.
Calling all DSO deals a scam goes too far. Some sources describe legitimate reasons a dentist may still choose one.
McLerran says certain structures let a dentist keep 20-49% practice equity, collect ongoing EBITDA distributions, or hold stock that could appreciate at future recap events. It gives a clean example: a dentist who sells at 7x and later exits part of retained equity at 14x can double that portion. Source: https://dentaltransitions.com/unpacking-dso-deal-structures/
White Coat Investor gives a seller-side account that is not purely negative. It says the Heartland model provided back-end services such as supply negotiation, compliance, payroll, marketing, HR, and mentoring, and says some doctors can buy ownership stakes in the larger platform. But it also warns that some DSOs are much more restrictive on labs, supplies, and clinical decisions, and notes Heartland's majority stake was acquired by KKR. Source: https://www.whitecoatinvestor.com/why-i-sold-my-practice/
So the fair conclusion is not "DSO offers are fake." It is "DSO offers often mix asset-sale proceeds with future labor and future investment risk, and sellers can fool themselves if they treat all of it like guaranteed sale price."
The Shared Practices transcript is opinionated, but it explains why many dentists feel burned later. Scott Leune argues that sellers can brag about a "five multiple" while forgetting debt, taxes, and the pay cut from going from owner to associate. In the transcript he says a seller who used to take home "$400 grand a year" might become an associate making "$200 grand a year," and warns that after debt and taxes "you may be negative multiple by selling." Source: https://sharedpracticespodcast.com/episodes/should-i-sell-to-a-dso/
That is not neutral analysis, but it is a useful counterweight to promotional DSO marketing because it focuses on cash actually kept, not enterprise value promised.
The post is directionally right. The recurring pattern across broker, legal, operator, and seller sources is that a DSO headline offer usually combines at least four economic layers: immediate cash, deferred or contingent cash, a required employment term, and sometimes rollover equity whose value depends on a future recap. Once you add management fees, normalized EBITDA adjustments, and LOI exclusivity, the number that got the seller excited at the start can be very different from the money, control, and certainty they end up with.
The precise scam is not necessarily fraud. It is compression: a buyer compresses an asset sale, a compensation plan, and an investment pitch into one flattering headline number, and many sellers do not separate those pieces until after they have already signed away leverage.